New drug approval: Dostarlimab - second line in advanced MSI endometrial cancer

xlomafota13 shared this article with you from Inoreader New drug approval: Dostarlimab - second line in advanced MSI endometrial cancer Via Association française pour l'étude du cancer Bull Cancer. 2021 May 13:S0007-4551(21)00177-6. doi: 10.1016/j.bulcan.2021.04.006. Online ahead of print. NO ABSTRACT PMID:33994164 | DOI:10.1016/j.bulcan.2021.04.006 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.